Part of the Peptide therapy guide

Is glutathione FDA-approved, and what does the research show?

At a glance

  • Glutathione, also written GSH, is an antioxidant your body makes itself 1.
  • It is not FDA-approved as a drug in its own right 2. FDA lists it in Category 1, "Under Evaluation," on its 503A nominations list, updated May 14, 2026 3.
  • It has been studied in people for skin lightening 4, 5, 6, Parkinson's disease 7, 8 and cystic fibrosis lung disease 9.
  • Trials gave it by mouth 4, 5, 1, on the skin, as oxidized glutathione 6, by intravenous infusion 7 and by inhalation 9.
  • JumpstartMD offers glutathione as one of its vitamin therapies.

Evidence strength

  1. No published studies found
  2. Animal or lab only
  3. Early human studies
  4. Human trials
  5. Approved for a use

Randomized, placebo-controlled trials in people have tested glutathione for skin lightening, Parkinson's disease and cystic fibrosis, with modest or no effects 4, 7, 9.

What is glutathione?

Glutathione is an antioxidant the body makes itself, "the most abundant endogenous antioxidant" in one trial's words 1. It regulates oxidative stress, the wear that reactive molecules put on cells, and immune function 1. In Asia it is widely taken to lighten skin 6.

Is glutathione FDA-approved?

No. Glutathione is not approved by FDA as a drug in its own right 2. Drugs@FDA lists only its oxidized form, glutathione disulfide, as one of eight ingredients of an eye-surgery irrigating solution, in two approved applications 2. They are BSS Plus (NDA 018469, Alcon, approved October 28, 1981) and NDA 020079 (Epic Pharma, approved November 27, 1991, now discontinued) 2. FDA lists glutathione itself in Category 1, "Bulk Drug Substances Under Evaluation," on its list of substances nominated for compounding under section 503A, updated May 14, 2026 3.

Section 503A is the part of federal law that covers pharmacies compounding a medicine to a clinician's prescription. The other two categories hold substances that "raise significant safety concerns" or were "nominated without adequate support" 3. In its January 2025 interim policy, FDA says it "does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance that … appears in 503A Category 1", under the conditions it lists 10. Glutathione is also sold as a dietary supplement 6, 1.

How does glutathione work?

In the lungs, glutathione is the main antioxidant in the fluid lining the airways 9. The skin effect is proposed, not proven, and one explanation is that glutathione steers melanin, the pigment that colors skin, toward its lighter form and away from the darker one 5. Whether glutathione taken by mouth is absorbed is contested. A systematic review doubts it 6. But a six-month trial in 54 healthy adults found glutathione levels rose 30 to 35 percent in erythrocytes (red blood cells), plasma and lymphocytes at the higher of two doses 1.

What does the research show?

Skin. Studied in people: a randomized, double-blind, placebo-controlled trial gave 60 healthy medical students in Bangkok oral glutathione or placebo for four weeks 4. Melanin fell at all six sites measured, but the drop beat placebo at only two, the right side of the face and the sun-exposed forearm 4. A 12-week randomized trial in 124 Asian women found that oral glutathione with L-cystine lightened skin and shrank facial dark spots, and the combination outdid glutathione alone 5. A 2019 systematic review of four studies called the evidence "still inconclusive" because of their quality and inconsistent findings 6.

Parkinson's disease. Studied in people: a randomized, double-blind pilot trial gave intravenous glutathione or placebo to 21 patients for four weeks and found no significant difference in symptom scores 7. A 2020 meta-analysis of seven randomized trials with 450 participants concluded that glutathione "may mildly improve motor scores," with no gain on the other symptom scales 8.

Lungs. Studied in people: a six-month randomized, double-blind trial gave inhaled glutathione or placebo to 153 people with cystic fibrosis 9. It found no clinically relevant gain in lung function, flare-ups or quality of life 9.

Beyond pigment, these sources hold no trial designed to test glutathione for skin aging as of November 9, 2026. The review notes only "a trend" toward fewer wrinkles and better elasticity 6.

What are the side effects?

The trials report few problems. In the 60 students, glutathione and placebo were "very well tolerated," but the authors warn that long-term safety "has not been established" 4. In the 21 Parkinson's patients, adverse events were similar in both groups and no one withdrew because of one 7. The meta-analysis of 450 participants found no difference in side effects between glutathione and control 8. In the 153 people with cystic fibrosis, adverse events were as common with inhaled glutathione as with placebo 9.

The skin review records "some adverse events but nonserious" 6. FDA's list places glutathione under evaluation, not among the substances it flags for significant safety concerns 3.

In sport

Glutathione is not named on the World Anti-Doping Agency's (WADA) 2026 Prohibited List 11. Under M2.2, though, it prohibits "intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period" outside hospital treatment, surgery or clinical diagnostic investigations 11. The Parkinson's trial gave glutathione intravenously 7. The list's S0 section also prohibits at all times "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use" 11. These sources do not settle whether S0 reaches glutathione.

What JumpstartMD offers

JumpstartMD's clinicians can prescribe glutathione after an evaluation, where it is appropriate for you. There is no FDA-approved glutathione drug; injectable glutathione is a compounded medicine 3, 2. JumpstartMD offers it as one of its vitamin therapies.

A JumpstartMD clinician available to talk through your goals
Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.

Frequently Asked Questions

Does glutathione lighten skin?

Modestly, in some trials, as in the 60 students whose four weeks of oral glutathione beat placebo at two of six skin sites 4. A systematic review calls the evidence "still inconclusive" 6.

Does glutathione help Parkinson's disease?

The evidence is thin, and a 21-patient pilot trial found no significant difference from placebo in symptom scores 7. A meta-analysis of 450 participants found a mild gain in motor scores only 8.

Is glutathione banned in sport?

It is not named on WADA's 2026 Prohibited List 11. Under M2.2, "intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period" are a prohibited method, except those received in hospital treatment, surgery or clinical diagnostic investigations 11.

References

  1. J. P. Richie Jr. et al., "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione," European journal of nutrition, vol. 54, no. 2, pp. 251-63, Mar. 2015, doi: 10.1007/s00394-014-0706-z. [Accessed: Nov. 9, 2026]. ↩
  2. U.S. Food and Drug Administration, "Drugs@FDA: FDA-Approved Drugs," application records NDA 018469 (BSS Plus, Alcon; original approval Oct. 28, 1981; marketing status Prescription) and NDA 020079 (Epic Pharma LLC; original approval Nov. 27, 1991; marketing status Discontinued), each listing glutathione disulfide 0.184 mg/mL among eight active ingredients of an irrigation solution. [Online]. Available: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018469 and https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020079 [Accessed: Nov. 9, 2026]. ↩
  3. U.S. Food and Drug Administration, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act," updated May 14, 2026. [Online]. Available: https://www.fda.gov/media/94155/download (accessed Nov. 9, 2026). ↩
  4. N. Arjinpathana, and P. Asawanonda, "Glutathione as an oral whitening agent: A randomized, double-blind, placebo-controlled study," Journal of Dermatological Treatment, vol. 23, no. 2, pp. 97-102, Apr. 2012, doi: 10.3109/09546631003801619. [Accessed: Nov. 9, 2026]. ↩
  5. J. Duperray, R. Sergheraert, K. Chalothorn, P. Tachalerdmanee, and F. Perin, "The effects of the oral supplementation of L‐Cystine associated with reduced L‐Glutathione‐GSH on human skin pigmentation: a randomized, double‐blinded, benchmark‐ and placebo‐controlled clinical trial," Journal of Cosmetic Dermatology, vol. 21, no. 2, pp. 802-813, Feb. 2022, doi: 10.1111/jocd.14137. [Accessed: Nov. 9, 2026]. ↩
  6. W. Dilokthornsakul, T. Dhippayom, and P. Dilokthornsakul, "The clinical effect of glutathione on skin color and other related skin conditions: A systematic review," Journal of Cosmetic Dermatology, vol. 18, no. 3, pp. 728-737, Jun. 2019, doi: 10.1111/jocd.12910. [Accessed: Nov. 9, 2026]. ↩
  7. R. A. Hauser, K. E. Lyons, T. McClain, S. Carter, and D. Perlmutter, "Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease," Movement Disorders, vol. 24, no. 7, pp. 979-983, May 2009, doi: 10.1002/mds.22401. [Accessed: Nov. 9, 2026]. ↩
  8. H. L. Wang, J. Zhang, Y. P. Li, L. Dong, and Y. Z. Chen, "Potential use of glutathione as a treatment for Parkinson's disease," Experimental and Therapeutic Medicine, vol. 21, no. 2, art. 125, Feb. 2021, doi: 10.3892/etm.2020.9557. [Accessed: Nov. 9, 2026]. ↩
  9. M. Griese et al., "Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial," American journal of respiratory and critical care medicine, vol. 188, no. 1, pp. 83-9, Jul. 2013, doi: 10.1164/rccm.201303-0427OC. [Accessed: Nov. 9, 2026]. ↩
  10. U.S. Food and Drug Administration, "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry," Jan. 2025, p. 13. [Online]. Available: https://www.fda.gov/media/174456/download [Accessed: Nov. 9, 2026]. ↩
  11. World Anti-Doping Agency, "The 2026 Prohibited List, International Standard," effective Jan. 1, 2026. [Online]. Available: https://www.wada-ama.org/en/prohibited-list [Accessed: Nov. 8, 2026]. ↩
Claim Your Consultation

Not ready yet?

Never miss an offer.

Get JumpstartMD special offers and updates by email. You can unsubscribe anytime.

By signing up, you agree to receive JumpstartMD marketing emails, including offers and updates. Unsubscribe anytime. Privacy Policy | California Privacy Policy